Life After Martin Shkreli — A Conversation With Turing's R&D Head

Dr. Eliseo Salinas had envisioned a career in academia, looking for ways to combat diseases like depression and Alzheimer’s. A psychiatrist by training, Salinas was studying circadian rhythms in depressed patients at Rene Descartes University in Paris in 1991 when he was contacted by the French pharmaceutical company, Synthelabo (now part of Sanofi). Synthelabo wanted Salinas to help lead clinical trials for their experimental neuroscience drugs.